What happened with PDSB today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
PDS Biotechnology Corporation is a clinical-stage drug developer focused on cancer treatments built around its Versamune platform. Its main candidates, PDS0101 and PDS01ADC, are still in clinical development. It also develops infectious-disease vaccines through its Infectimune platform, with near-term work focused on influenza.
The company has no products approved for sale and has not generated product revenue. Share investors and lenders have supplied most of its operating funds, which primarily support research and development. Continuing development depends on raising additional capital; inadequate funding could force it to scale back or stop programs.
PDS expects PDS0101, alone or combined with PDS01ADC, to supply substantially all future revenue if approved. That requires successful further trials, regulatory approval and commercialization, with sales depending on physician acceptance and government and private-insurer coverage. It relies on outside manufacturers for drug supplies rather than operating its own factories. PDS01ADC is licensed from Merck KGaA under an agreement requiring milestone payments and royalties on any product sales.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
PDS's prospects hinge on clinical success and financing; its PDS01ADC license comes from Germany's Merck KGaA, not Merck & Co.
INOVIO Pharmaceuticals and PDS are developing immune-based treatments for HPV-associated disease, so progress in INOVIO's competing cancer programs matters for PDS. INOVIO had no product sales through 2025; its revenue came from licensing, milestones and research agreements rather than sales of approved treatments.
Precigen's PRGN-2009 competes with PDS's immune-based treatments for HPV-associated cancers, using a different platform to deliver the treatment. Watch PRGN-2009's clinical progress for this comparison, rather than sales of Papzimeos, which Precigen sells in the United States for adults with recurrent respiratory papillomatosis.
Bicara Therapeutics and PDS could compete for head-and-neck cancer patients and for use alongside drugs that release the brakes on immune cells, called checkpoint inhibitors. Watch Bicara's Phase 1/1b results for ficerafusp alfa with pembrolizumab: Bicara supplies its candidate and runs the trial, while MSD supplies pembrolizumab.
Xilio Therapeutics competes with PDS01ADC to stimulate immune activity against advanced solid tumors using IL-12; Xilio designs its treatment to stay inactive until activated inside tumors. Its efarindodekin alfa Phase 2 results are the comparison to watch, with a data package for Gilead's option decision expected in the first half of 2027.
Werewolf Therapeutics' WTX-330 and PDS01ADC are competing experimental IL-12 cancer treatments aimed at overcoming the limits of stimulating immunity throughout the body. Werewolf designs its drugs to activate inside tumors rather than normal tissues, making WTX-330's efficacy and safety the key comparison for PDS.
Merck & Co.'s Keytruda is both part of PDS0101 combination development and a head-and-neck cancer treatment in its own right. Merck & Co. is not Merck KGaA, the separate company that licenses PDS01ADC to PDS.
Pyxis Oncology and PDS both develop head-and-neck cancer treatments, so better efficacy or safety results at Pyxis could change PDS's competitive outlook. Watch MICVO, its antibody-linked drug candidate: Pyxis focused development resources there while pausing other programs.
BioNTech and PDS develop immune-based treatments for HPV-associated cancers, making their clinical results relevant to the same treatment market. For this tie, watch BioNTech's HPV-associated cancer results rather than sales of its commercial COVID-19 vaccine, Comirnaty.
ImmunityBio competes with PDS in IL-12 cancer development, while its marketed IL-15 treatment ANKTIVA offers a separate benchmark for selling immune-stimulating therapies. Watch ANKTIVA revenue from use with BCG in adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors—not as evidence that PDS01ADC works.
Zymeworks and PDS compete to establish IL-12 as an effective cancer treatment, so progress in Zymeworks' IL-12 programs matters for PDS01ADC. Zymeworks also seeks milestone payments and royalties from partners, but those payments are distinct from evidence that its IL-12 approach works.
Fed Interest Rate Decision
The Fed’s decision on its benchmark interest rate matters to PDS Biotechnology because it can affect the interest it pays on its senior secured debentures and the cash available for research and development.
Expected4.0%Last release4.0%
If it comes in above expectations
If the policy rate is above expectations, higher economy-wide rates may push prime above its 6% floor, increasing interest expense and cash needed for debt payments and leaving less for developing its candidates.
If it comes in below expectations
If the policy rate is below expectations, lower economy-wide rates may reduce prime and, once it falls below the 6% floor, lower debenture interest expense and cash needed for debt payments, leaving more for candidate development.
Werewolf Therapeutics, Inc. earningsHOWL
If Werewolf Therapeutics reports efficacy and safety progress for WTX-330, its report will offer a direct competitive benchmark for PDS's IL-12 treatment, PDS01ADC.
Look for evidence of anti-cancer activity from WTX-330 and whether its safety allows development to continue. Activity with manageable safety would raise the competitive bar PDS01ADC faces from Werewolf's tumor-activated approach; limited activity or safety concerns would ease that pressure, but would not show that PDS01ADC works. The takeaway is about competition between two experimental IL-12 treatments, not a direct comparison of clinical results.
PDS Biotechnology Corporation earningsThis company
PDS Biotechnology has no product revenue, so this report will show whether cash use and research spending are making its clinical programs harder to sustain.
Read the cash balance, operating cash outflow and research spending together. Less cash outflow while programs continue would suggest the available funds can last longer; faster cash use, or lower spending alongside slower development, would point to more financing pressure and possible delays. The key is whether funding can keep pace with clinical development, not simply whether the loss narrowed.
Precigen, Inc. earningsPGEN
If Precigen reports clinical progress for PRGN-2009, its report will show how much competitive pressure another immune-based treatment for HPV-associated cancers could bring to PDS Biotechnology.
Focus on PRGN-2009's clinical progress, not revenue from Precigen's marketed Papzimeos, which is not evidence about this candidate. Progress would add clinical support for another treatment seeking HPV-associated cancer patients and make competition for PDS's related programs more tangible; limited or stalled progress would weaken that signal, but would not show that PDS's treatments work. The point is progress in a shared patient market, not sales of a different product.
